DHS ordered to map biodetection gaps and plan upgrades

What it does

This bill directs the Department of Homeland Security to assess how it currently uses Department of Energy national laboratories for biodetection research, and to develop a strategy for coordinating with those labs to improve biodetection technologies—particularly for the BioWatch program that monitors for biological threats. DHS must report back to Congress within 180 days with a plan to acquire and deploy better biodetection equipment, evaluate performance, and work with state, local, tribal, and private partners on future biodetection programs.

Why we flagged it

The bill is fundamentally a directive for strategic assessment and coordination of biodetection capabilities across federal agencies and partners. It is a planning and accountability measure, not a substantive appropriation or regulatory change, focused on improving public biosecurity infrastructure.

What the text implies

• The bill's emphasis on 'periodic external evaluations' and 'contingency plans' suggests DHS may be acknowledging performance gaps in the existing BioWatch network, potentially signaling that current biodetection coverage is inadequate.
• Requirement to work with 'private sector' partners on biodetection programs may create opportunities for private companies to influence or capture biodetection technology standards and procurement, depending on how partnerships are structured.
• The 180-day assessment timeline is relatively tight; if DHS lacks internal capacity or data, the strategy may be generic or incomplete, reducing the bill's practical impact.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill mandates assessment and strategic planning for biodetection capabilities that protect public health and safety from biological threats. It requires transparency through congressional reporting and emphasizes coordination with state/local/tribal governments and the private sector, improving accountability and potentially strengthening the nation's biosecurity posture without imposing new restrictions on citizens.

Who stands to gain

• biodetection technology vendors and manufacturers
• Department of Energy national laboratories (increased contract work)
• systems integrators and consultants specializing in biosecurity

Named in the bill

Department of Homeland Security (DHS), Department of Energy (DOE), BioWatch program, Countering Weapons of Mass Destruction Office, House Committee on Homeland Security, Senate Committee on Homeland Security and Governmental Affairs, Comptroller General of the US

Where it stands

1 cosponsor: 1 Republicans.

• Jan 23, 2025 — Introduced · Congress.gov: “Introduced in House”
• Jan 23, 2025 — Referred to House Committee on Homeland Security and Senate Committee on Homeland Security and Governmental Affairs · Congress.gov: “Referred to the Subcommittee on Emergency Management and Technology”
• Mar 10, 2025 — Floor vote scheduled · Congress.gov: “Mr. Green (TN) moved to suspend the rules and pass the bill”
• Mar 11, 2025 — Passed the House · Congress.gov: “Motion to reconsider laid on the table Agreed to without objection”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $20,000 in lobbying spend. A filing names 21 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Dale Strong, the sponsor, reported $659,420 in PAC receipts in the 2026 cycle.

• Chartercare Health of Ri (forrmerly Known As Chartercare Health Partners) — $20,000 on 1 filing

Lobbying Disclosure Act filings through Jul 23, 2026. A filing shows who paid to lobby on a bill it names, not what changed.